查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2000597

心血管吻合裝置市場：依產品類型、機制、手術類型、外科手術類型及最終用戶分類－2026-2032年全球市場預測

Cardiovascular Anastomosis Devices Market by Product Type, Mechanism, Procedure Type, Surgery Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，心血管吻合裝置市場價值將達到 21.9 億美元，到 2026 年將成長至 24.3 億美元，到 2032 年將達到 46.5 億美元，複合年成長率為 11.34%。

主要市場統計數據
基準年 2025 21.9億美元
預計年份：2026年 24.3億美元
預測年份 2032 46.5億美元
複合年成長率 (%) 11.34%

對目前心血管吻合術的設備生態系統、臨床考量和營運重點進行清晰權威的指南。

心血管吻合裝置融合了外科技術、材料科學和系統級醫療服務。本文介紹了目前用於在各種手術中建立和固定血管及心臟連接的工具，揭示了裝置的幾何形狀、作用機制和臨床工作流程如何相互作用並影響治療結果。該領域已從手動縫合發展到機械化、能量輔助和混合解決方案，旨在提高手術的可重複性、縮短手術時間並最大限度地減少併發症。

微創手術的趨勢、材料技術的快速發展、器械互通性的提高以及採購模式的演變，正在重新定義外科吻合術的實踐。

多項變革正在重塑心血管吻合器材的設計、應用和商業化，並對臨床、生產和醫保報銷等領域產生影響。首先，微創和機器人輔助手術的穩定發展，推動了對能夠在有限入路下實現穩定、可重複吻合的器械的需求成長。這一趨勢加速了器械在形狀、靈活性和與機器人平台整合方面的迭代改進。因此，產品開發現在更加重視模組化介面和相容性標準，以加快臨床應用並減輕訓練負擔。

美國關稅趨勢變化如何推動供應鏈重組、價格壓力以及本地製造業韌性機會的實證分析。

主要市場政策變化導致的關稅徵收和提高，可能會對心血管吻合器材製造商和經銷商的供應鏈選擇、籌資策略和零件成本產生重大影響。如果進口關稅訂定或提高，依賴跨境採購精密金屬零件、先進聚合物、電控系統或機器人子系統的公司將需要重新評估其供應商關係和庫存管理實踐，以維持獲利能力和供應穩定性。

透過整合產品類型、機制、流程和最終用戶參數的多維細分，我們確定了精確的臨床和商業性目標領域。

要了解產品和臨床細分市場，需要採用多層次的細分方法，以明確哪些領域能夠最有效地部署創新和商業化。按產品類型分類，該器械市場包括夾子、縫合器和縫合器械。夾子用於快速控制血管，止血夾和血管夾是典型的例子。止血夾本身有金屬和聚合物兩種材質，兼顧了耐用性和與影像診斷的兼容性。縫合器有圓形和直線形兩種結構，直線形縫合器再依組織厚度和抗滲漏性分為非加強型和加強型。縫合器械涵蓋自動縫合和手動縫合技術，其中自動縫合又細分為手持式和機器人縫合器，以滿足不同的自動化程度和手術複雜程度的需求。

區域臨床重點、法規環境和供應鏈發展如何對美洲、歐洲、中東和非洲以及亞太地區的醫療設備部署產生不同的影響？

區域趨勢塑造了部署路徑、監管障礙和供應鏈設計，進而影響策略和實施。在美洲，臨床上對微創冠狀動脈和周邊血管介入治療的關注，與成熟的報銷體系和完善的醫院採購流程相契合。主要市場的醫療機構優先考慮能夠顯著縮短手術時間、降低併發症率並與現有手術平台相容的器械。同時，區域製造商和契約製造在提供本地化供應和快速補貨方面發揮著至關重要的作用，這有利於高運作的醫療機構。

對醫療器材領域的競爭定位、夥伴關係動態、供應商重點以及塑造領導地位的創新路徑進行深入分析。

心血管吻合器材市場的競爭格局複雜多樣，既有成熟的醫療設備製造商，也有高度專業化的中型創新企業，以及數量不斷成長的科技型Start-Ups。成熟的製造商正憑藉其廣泛的銷售管道、豐富的監管合規經驗和現有的臨床關係，迅速拓展分銷網路；而小規模的企業則透過推出先進的能量控制演算法、新型可吸收聚合物和緊湊型機器人縫合模組等創新功能，吸引早期採用的外科醫生和策略收購公司。

採取切實可行的策略措施和營運策略，加快招募速度，降低價值鏈風險，並加強臨床和商業性價值提案。

產業領導企業應採取一系列協調一致的策略措施，以因應產品設計、市場准入和供應鏈韌性等問題。首先，應優先考慮模組化產品架構，以實現分階段升級和簡化監理申報流程。這將縮短產品部署時間，並使製造商能夠在無需進行重大重新設計的情況下實施針對性改進。其次，應投資於收集將設備性能與臨床結果和營運指標連結起來的證據。可操作的臨床試驗、參與註冊研究以及對手術全期工作流程的研究將增強醫院和門診診所採購產品的合理性。

一個透明的混合方法研究框架，整合了臨床醫生訪談、監管審查、供應鏈映射和證據檢驗驗證，以確保獲得可靠的見解。

本研究採用混合方法，結合定性一手檢驗和定量二手資料進行三角驗證，對醫療設備的性能、推廣應用促進因素和供應鏈脆弱性進行了多維度觀點。一手調查方法包括對心血管外科醫師、採購負責人、臨床營運經理和生產主管進行結構化訪談，並輔以手術室觀察資料和醫療設備訓練模擬資料。這些研究工作獲得了關於醫療醫療設備易用性、推廣應用挑戰和臨床醫生偏好的第一手資料。

我們透過提供簡潔、全面的分析，將臨床創新、營運韌性和商業策略連結起來，幫助經營團隊在其醫療器材專案中做出穩健的決策。

總之，心血管吻合器材市場正朝著兼顧臨床療效和操作效率的解決方案轉變。材料和能源供應方面的創新，以及微創和機器人手術的普及，正在重新定義臨床醫生對器械的需求，同時也提升了互通性和循證價值提案的重要性。供應鏈壓力和貿易政策的變化進一步凸顯了彈性籌資策略和敏捷生產的重要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 心血管吻合器材市場：依產品類型分類

  • 夾子
    • 止血夾
      • 金屬夾
      • 聚合物夾
    • 血管夾
  • 訂書機
    • 圓形訂書機
    • 直式訂書機
      • 未加固型
      • 加強型
  • 縫合裝置
    • 自動縫合
      • 手持式縫合器
      • 機器人縫合裝置
    • 手工縫合

第9章：心血管吻合裝置市場：依機制分類

  • 黏合劑
    • 纖維蛋白膠
    • 合成密封劑
  • 夾鉗
  • 壓縮
    • 吻合環
    • 扣上
      • 生物可吸收扣
      • 金屬扣
  • 能量公式
    • 電暖型
    • 雷射
    • 超音波
  • 裝訂

第10章：依手術類型分類的心血管吻合器市場

  • 冠狀動脈繞道手術
    • 非泵送
    • 泵浦上
  • 周邊血管
    • 頸動脈
    • 股膕窩
    • 腎
  • 閥門維修

第11章：依手術類型分類的心血管吻合器市場

  • 冠狀動脈繞道手術手術
    • 心臟外冠狀動脈繞道手術繞道手術
    • 非心肺體外迴圈冠狀動脈繞道手術手術
    • 微創冠狀動脈繞道手術手術
  • 瓣膜手術
    • 主動脈瓣膜手術
    • 二尖瓣手術
    • 三尖瓣和肺動脈瓣手術
  • 主動脈手術
    • 動脈瘤修復手術
    • 分離修復手術
    • 瓣膜根部置換術
  • 先天性心臟疾病手術
    • 室間隔缺損修補術
    • 分流手術
    • 複雜先天性心臟疾病的修復手術
  • 心臟移植及心室輔助裝置
    • 心臟移植
    • 植入心室輔助裝置
  • 周邊血管繞道手術
    • 下肢繞道手術
    • 上肢繞道手術
    • 頸動脈旁路手術
  • 混合治療和血管內治療
    • 混合冠狀動脈再灌注療法
    • 主動脈雜交修復術

第12章 心血管吻合器市場：依最終用戶分類

  • 日間手術中心
  • 醫院
  • 專科診所

第13章 心血管吻合器市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 心血管吻合器材市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 心血管吻合器材市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國心血管吻合裝置市場

第17章：中國心血管吻合器市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Boston Scientific Corporation
  • Cardio Medical GmbH
  • Cook Medical Incorporated
  • CryoLife, Inc.
  • Edwards Lifesciences Corporation
  • Getinge AB
  • Johnson & Johnson
  • LeMaitre Vascular, Inc.
  • LivaNova PLC
  • Medtronic plc
  • Peters Surgical SASU
  • Teleflex Incorporated
  • TERUMO Corporation
  • VasoPrep Surgical, LLC
  • Vitalitec International, Inc.
  • WL Gore & Associates, Inc.
Product Code: MRR-8C74ADFBF9A7

The Cardiovascular Anastomosis Devices Market was valued at USD 2.19 billion in 2025 and is projected to grow to USD 2.43 billion in 2026, with a CAGR of 11.34%, reaching USD 4.65 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.19 billion
Estimated Year [2026] USD 2.43 billion
Forecast Year [2032] USD 4.65 billion
CAGR (%) 11.34%

A clear and authoritative orientation to the current device ecosystem, clinical considerations, and operational priorities shaping cardiovascular anastomosis today

Cardiovascular anastomosis devices sit at the intersection of surgical technique, materials science, and systems-level healthcare delivery. This introduction frames the contemporary landscape of tools used to establish and secure vascular and cardiac connections during a wide range of procedures, highlighting the ways that device form factors, mechanism of action, and clinical workflows interact to influence outcomes. The discipline has advanced from manual suturing toward mechanized, energy-assisted, and hybrid solutions designed to standardize reproducibility, reduce operative time, and mitigate complications.

Across the portfolio of devices discussed here, clinicians and healthcare organizations increasingly evaluate performance not only by ease of use but by durability, hemostasis efficiency, and compatibility with minimally invasive and robotic approaches. The integration of new polymers, metals, and energy delivery systems has expanded options for surgeons while adding complexity to procurement, training, and regulatory pathways. As stakeholders adopt novel approaches, the balance between device efficacy, clinician ergonomics, and total procedure cost becomes central to commercial conversations.

This introduction sets expectations for the following sections: an analysis of the tectonic shifts reshaping practice, a scenario-based view of tariff impacts, segmentation-driven insights that clarify product and clinical niches, and regional and competitive intelligence designed to inform practical strategy. The aim is to equip decision-makers with clear thematic takeaways that support immediate tactical choices and mid-term strategic planning.

How minimally invasive trends, materials breakthroughs, device interoperability, and evolving procurement models are redefining surgical anastomosis practices

Several transformative shifts are reshaping how cardiovascular anastomosis devices are designed, adopted, and commercialized, with implications that extend across clinical, manufacturing, and reimbursement domains. First, the steady move toward minimally invasive and robotic-assisted surgery has increased demand for devices that provide consistent, reproducible anastomoses within constrained access corridors; this trend is accelerating iterative refinements in form factor, articulation, and integration with robotic platforms. As a result, product development now emphasizes modular interfaces and compatibility standards that allow quicker clinical adoption and lower training burden.

Second, materials innovation-ranging from polymer formulations for absorbable components to new alloys and coatings for hemostatic clips-has expanded device longevity and biocompatibility while enabling engineers to reduce profile footprint and improve deployment reliability. Concurrently, energy-based technologies such as electrothermal and ultrasonic modalities are being refined to deliver controlled tissue effects, reducing bleeding and shortening operative time when properly matched to the clinical indication.

Third, procurement dynamics are evolving as ambulatory surgery centers gain greater procedural volume and hospitals pursue value-based metrics; this has heightened focus on total procedural cost, inventory optimization, and interoperability with existing devices. Lastly, regulatory and clinical-evidence expectations are rising, driving firms to invest in robust comparative studies and real-world evidence generation that demonstrate not only safety and efficacy but also downstream economic and workflow benefits. Taken together, these forces are producing a market environment where technical differentiation, clinical validation, and distribution agility determine the leaders in device adoption.

A practical analysis of how evolving US tariff dynamics drive supply chain reengineering, pricing pressure, and opportunities for local manufacturing resilience

The imposition and escalation of tariffs originating from policy shifts in major markets can materially influence supply chain choices, sourcing strategies, and component economics for manufacturers and distributors of cardiovascular anastomosis devices. When import levies are introduced or increased, firms that rely on cross-border sourcing for precision metal components, advanced polymers, electronic control units, or robotic subsystems must reassess supplier relationships and inventory practices to maintain margin and availability.

In practical terms, tariffs often catalyze near-term cost passthrough to buyers or compression of supplier margins, creating pressure to redesign devices for fewer tariff-sensitive inputs or to qualify local manufacturers who can supply key subassemblies. Manufacturers may pursue regional production hubs or toll-manufacturing agreements to mitigate exposure to targeted levies. At the same time, elevated import costs can accelerate vertical integration for components with high tariff risk, prompting manufacturers to acquire or partner with specialized suppliers to secure continuity and reduce unit cost volatility.

Clinically, procurement teams and hospital systems respond to tariff-driven price changes by tightening evaluation criteria, increasing competitive bidding, and prioritizing multi-use or reusable solutions where appropriate. Reimbursement administrators and value committees may demand clearer evidence of cost-benefit under new input-cost realities. For innovation-driven companies, tariffs create both challenges and opportunities: while they can increase near-term commercial friction, they also incentivize product simplification, localization of sensitive supply chains, and the development of incremental improvements that reduce reliance on imported materials and finished goods. Thus, tariff scenarios should be integrated into strategic planning as an ongoing supply-chain and pricing risk that requires coordinated responses across procurement, regulatory affairs, and product development.

A multi-dimensional segmentation synthesis that aligns product type, mechanism, procedure, and end-user parameters to reveal precise clinical and commercial target zones

Understanding product and clinical niches requires a layered segmentation approach that clarifies where innovation and commercialization can most effectively be targeted. By product type, the device universe encompasses clips, staplers, and suture devices. Clips are used for rapid vessel control and are typified by hemostatic clips and ligating clips; hemostatic clips themselves are delivered in metal and polymer variants that trade off permanence and imaging compatibility. Staplers include circular and linear configurations, and within linear staplers manufacturers distinguish between non-reinforced and reinforced variants to address tissue thickness and leak resistance. Suture devices span automated suturing and manual suturing techniques, with the automated category further divided into handheld suturators and robotic suturators that target different levels of automation and procedural complexity.

By mechanism of action, devices are organized across adhesive solutions, clamping systems, compression mechanisms, energy-based modalities, and stapling. Adhesive technologies include biologic fibrin sealants and synthetic sealants, each offering distinct handling and hemostatic profiles. Compression strategies cover anastomotic rings and buckles, and buckles may be bioabsorbable or metal depending on the intended permanence. Energy-based devices deploy electrothermal, laser, or ultrasonic effects to seal tissue and control bleeding while minimizing collateral thermal injury.

By procedure type, device selection aligns with the clinical context: coronary bypass surgery-performed off-pump or on-pump-creates one set of anastomotic challenges, whereas peripheral vascular procedures such as carotid, femoropopliteal, and renal interventions demand devices optimized for vessel size, accessibility, and plaque burden. Valve repair procedures introduce additional anatomical and hemodynamic constraints that influence device selection and deployment technique. Finally, end-user segmentation highlights the delivery environment: ambulatory surgery centers, hospitals, and specialty clinics each impose distinct requirements in terms of device footprint, sterilization workflows, and staff training. Appreciating these interlocking segmentation layers enables firms to tailor product design, clinical evidence generation, and commercialization pathways to the realities of distinct clinical and operational settings.

How regional clinical priorities, regulatory environments, and supply chain footprints differentially influence device adoption across Americas, EMEA, and Asia-Pacific

Regional dynamics shape adoption pathways, regulatory hurdles, and supply-chain design in ways that affect strategy and execution. In the Americas, clinical emphasis on minimally invasive coronary and peripheral interventions intersects with a mature reimbursement infrastructure and sophisticated hospital purchasing processes. Providers in major markets prioritize devices that demonstrably reduce operating time, lower complication rates, and integrate with existing surgical platforms. Meanwhile, regional manufacturers and contract manufacturers play a significant role in providing localized supply and rapid replenishment, which benefits high-volume centers.

The Europe, Middle East & Africa region presents a heterogeneous landscape where regulatory alignment across countries and strong national procurement agencies can accelerate adoption when evidence is compelling, but fragmentation across markets requires tailored regulatory and reimbursement strategies. Several European markets have high expectations for real-world evidence and cost-effectiveness data, and procurement bodies often demand long-term safety information for devices intended to be permanent or semi-permanent.

Asia-Pacific is characterized by rapid growth in procedural volumes, expanding investment in hospital infrastructure, and a dual market structure that includes both high-end tertiary care centers and resource-constrained facilities. Local OEMs and regional supply chains are increasingly sophisticated, and multinational vendors often pursue partnerships or local production to meet regulatory and cost requirements. Across regions, companies that align product portfolios to local procedural patterns, regulatory timing, and purchasing models gain the clearest path to sustained adoption.

An incisive review of competitive positioning, partnership dynamics, supplier concentration, and the innovation pathways shaping device leadership

Competitive dynamics in cardiovascular anastomosis devices are shaped by a mix of incumbent medical-device firms, specialized mid-sized innovators, and a growing cohort of technology-focused startups. Established manufacturers leverage broad commercial channels, regulatory experience, and existing clinical relationships to scale distribution quickly, while smaller players advance disruptive features-such as advanced energy control algorithms, novel absorbable polymers, or compact robotic suturing modules-that attract early-adopter surgeons and strategic acquirers.

Partnerships and co-development agreements between device companies and robotic platform providers have intensified as both sides seek to ensure interoperability and bundled clinical value propositions. Cross-disciplinary collaboration between materials scientists, clinical researchers, and systems engineers has produced a pipeline of incremental innovations that improve handling, reduce device profile, and enhance hemostasis. At the same time, regulatory pathways emphasizing clinical evidence and post-market surveillance have raised the bar for new entrants, making clinical trial design, registry participation, and formal health-economics analysis essential components of go-to-market plans.

Supplier concentration for specialized components-precision stamping for metal clips, custom polymer extrusion, and microelectronics for energy delivery systems-creates strategic dependencies that influence pricing and lead times. Consequently, firms that maintain diversified supplier bases, invest in secondary sourcing, or internalize key capabilities are better positioned to manage disruption. Competitive advantage increasingly accrues to organizations that can pair clinical efficacy with demonstrable workflow improvements and clear economic narratives that resonate with hospital administrators and integrated delivery networks.

Practical strategic moves and operational measures to accelerate adoption, de-risk supply chains, and strengthen clinical and commercial value propositions

Industry leaders should adopt a coordinated set of strategic actions that address product design, commercial access, and supply-chain resilience. First, prioritize modular product architectures that enable incremental upgrades and simplified regulatory submissions; this reduces time-to-adoption and allows manufacturers to introduce targeted improvements without broad redesign. Second, invest in evidence generation that links device performance to clinical outcomes and operational metrics; pragmatic trials, registry participation, and perioperative workflow studies will strengthen purchasing cases in both hospitals and ambulatory centers.

Third, diversify sourcing and consider regional manufacturing footprints to mitigate tariff exposure and logistics risk; dual-sourcing agreements, qualified contract manufacturers in strategic geographies, and selective vertical integration for high-risk components will reduce vulnerability to trade disruptions. Fourth, enhance surgeon training pathways through simulation, proctoring networks, and digital learning platforms to accelerate clinician confidence and shorten the adoption curve for new devices or techniques. Fifth, tailor commercial models to end-user needs by offering bundled procedural kits for ambulatory centers and specialized support packages for high-acuity hospitals, thereby aligning value propositions with purchaser incentives.

Finally, maintain an active regulatory engagement plan and monitor evolving standards for energy-based and implantable components. Engaging early with regulators and reimbursement stakeholders can expedite market access while ensuring that clinical data collection supports long-term surveillance and economic assessment. Together, these actions form a pragmatic roadmap that balances near-term operational resilience with long-term clinical and commercial differentiation.

A transparent mixed-methods research framework integrating clinician interviews, regulatory review, supply-chain mapping, and evidence triangulation to ensure robust insights

The research applied a mixed-methods approach that triangulated primary qualitative engagement with quantitative secondary data to build a multi-perspective view of device performance, adoption drivers, and supply-chain vulnerabilities. Primary inputs included structured interviews with cardiac and vascular surgeons, procurement officers, clinical affairs leaders, and manufacturing executives, supplemented by observational inputs from procedure rooms and device training simulations. These engagements provided first-hand insights into device usability, deployment challenges, and clinician preferences.

Secondary research encompassed systematic reviews of peer-reviewed clinical literature, regulatory filings, patent landscapes, and technology white papers to validate performance claims and trace innovation trajectories. Supply-chain mapping combined customs data, supplier directories, and manufacturing footprint analysis to identify concentration risks and potential nearshoring opportunities. Methodological rigor was ensured through cross-validation of findings across multiple data sources, sensitivity testing of scenario assumptions, and advisory review by clinical and industry experts.

Ethical research practices were observed throughout, and proprietary data were handled under strict confidentiality protocols. The synthesis prioritized actionable intelligence that speaks directly to procurement, R&D, and commercial planning needs without relying on unverifiable claims, ensuring that recommendations are grounded in observable trends and corroborated practitioner experience.

A concise synthesis linking clinical innovation, operational resilience, and commercial strategy to inform confident executive decision-making in device programs

In closing, the cardiovascular anastomosis device landscape is transitioning toward solutions that harmonize clinical efficacy with operational efficiency. Innovations in materials and energy delivery, along with the spread of minimally invasive and robotic approaches, are redefining what clinicians expect from devices while amplifying the importance of interoperability and evidence-based value propositions. Supply-chain pressures and trade-policy shifts further underscore the need for flexible sourcing strategies and manufacturing agility.

Decision-makers who align product development with clear procedural needs, invest in rigorous clinical and economic evidence, and adopt resilient manufacturing and procurement practices will be best positioned to capture sustainable adoption. Equally, organizations that prioritize end-user training, simplified device interfaces, and targeted regional strategies can accelerate uptake in high-opportunity clinical segments. The synthesis presented here is intended to inform tactical choices and strategic investment priorities that drive both improved patient outcomes and durable commercial performance.

By bringing clinical insight, supply-chain realism, and competitive clarity together, this analysis supports executives and clinical leaders in making measured, high-confidence decisions about where to invest, how to mitigate risk, and how to scale innovations across diverse healthcare settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cardiovascular Anastomosis Devices Market, by Product Type

  • 8.1. Clips
    • 8.1.1. Hemostatic Clips
      • 8.1.1.1. Metal Clips
      • 8.1.1.2. Polymer Clips
    • 8.1.2. Ligating Clips
  • 8.2. Staplers
    • 8.2.1. Circular Staplers
    • 8.2.2. Linear Staplers
      • 8.2.2.1. Non Reinforced
      • 8.2.2.2. Reinforced
  • 8.3. Suture Devices
    • 8.3.1. Automated Suturing
      • 8.3.1.1. Handheld Suturer
      • 8.3.1.2. Robotic Suturer
    • 8.3.2. Manual Suturing

9. Cardiovascular Anastomosis Devices Market, by Mechanism

  • 9.1. Adhesive
    • 9.1.1. Fibrin Sealants
    • 9.1.2. Synthetic Sealants
  • 9.2. Clamping
  • 9.3. Compression
    • 9.3.1. Anastomotic Rings
    • 9.3.2. Buckles
      • 9.3.2.1. Bioabsorbable Buckles
      • 9.3.2.2. Metal Buckles
  • 9.4. Energy Based
    • 9.4.1. Electrothermal
    • 9.4.2. Laser
    • 9.4.3. Ultrasonic
  • 9.5. Stapling

10. Cardiovascular Anastomosis Devices Market, by Procedure Type

  • 10.1. Coronary Bypass
    • 10.1.1. Off Pump
    • 10.1.2. On Pump
  • 10.2. Peripheral Vascular
    • 10.2.1. Carotid
    • 10.2.2. Femoropopliteal
    • 10.2.3. Renal
  • 10.3. Valve Repair

11. Cardiovascular Anastomosis Devices Market, by Surgery Type

  • 11.1. Coronary Artery Bypass Grafting
    • 11.1.1. On-Pump Coronary Bypass
    • 11.1.2. Off-Pump Coronary Bypass
    • 11.1.3. Minimally Invasive Coronary Bypass
  • 11.2. Valve Surgery
    • 11.2.1. Aortic Valve Procedures
    • 11.2.2. Mitral Valve Procedures
    • 11.2.3. Tricuspid And Pulmonic Valve Procedures
  • 11.3. Aortic Surgery
    • 11.3.1. Aneurysm Repair
    • 11.3.2. Dissection Repair
    • 11.3.3. Root Replacement
  • 11.4. Congenital Heart Surgery
    • 11.4.1. Septal Defect Repair
    • 11.4.2. Shunt Procedures
    • 11.4.3. Complex Congenital Repairs
  • 11.5. Heart Transplant And Ventricular Assist Device
    • 11.5.1. Heart Transplant
    • 11.5.2. Ventricular Assist Device Implantation
  • 11.6. Peripheral Vascular Bypass
    • 11.6.1. Lower Extremity Bypass
    • 11.6.2. Upper Extremity Bypass
    • 11.6.3. Carotid Bypass
  • 11.7. Hybrid And Endovascular Procedures
    • 11.7.1. Hybrid Coronary Revascularization
    • 11.7.2. Aortic Hybrid Repair

12. Cardiovascular Anastomosis Devices Market, by End User

  • 12.1. Ambulatory Surgery Centers
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Cardiovascular Anastomosis Devices Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cardiovascular Anastomosis Devices Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cardiovascular Anastomosis Devices Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Cardiovascular Anastomosis Devices Market

17. China Cardiovascular Anastomosis Devices Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. B. Braun Melsungen AG
  • 18.7. Baxter International Inc.
  • 18.8. Boston Scientific Corporation
  • 18.9. Cardio Medical GmbH
  • 18.10. Cook Medical Incorporated
  • 18.11. CryoLife, Inc.
  • 18.12. Edwards Lifesciences Corporation
  • 18.13. Getinge AB
  • 18.14. Johnson & Johnson
  • 18.15. LeMaitre Vascular, Inc.
  • 18.16. LivaNova PLC
  • 18.17. Medtronic plc
  • 18.18. Peters Surgical SASU
  • 18.19. Teleflex Incorporated
  • 18.20. TERUMO Corporation
  • 18.21. VasoPrep Surgical, LLC
  • 18.22. Vitalitec International, Inc.
  • 18.23. W. L. Gore & Associates, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY MECHANISM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SURGERY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CLIPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CLIPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CLIPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CLIPS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HEMOSTATIC CLIPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HEMOSTATIC CLIPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HEMOSTATIC CLIPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HEMOSTATIC CLIPS, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY METAL CLIPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY METAL CLIPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY METAL CLIPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY POLYMER CLIPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY POLYMER CLIPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY POLYMER CLIPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LIGATING CLIPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LIGATING CLIPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LIGATING CLIPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY STAPLERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY STAPLERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY STAPLERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY STAPLERS, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CIRCULAR STAPLERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CIRCULAR STAPLERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CIRCULAR STAPLERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LINEAR STAPLERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LINEAR STAPLERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LINEAR STAPLERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LINEAR STAPLERS, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY NON REINFORCED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY NON REINFORCED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY NON REINFORCED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY REINFORCED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY REINFORCED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY REINFORCED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SUTURE DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SUTURE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SUTURE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SUTURE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AUTOMATED SUTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AUTOMATED SUTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AUTOMATED SUTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AUTOMATED SUTURING, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HANDHELD SUTURER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HANDHELD SUTURER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HANDHELD SUTURER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ROBOTIC SUTURER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ROBOTIC SUTURER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ROBOTIC SUTURER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY MANUAL SUTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY MANUAL SUTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY MANUAL SUTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ADHESIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ADHESIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ADHESIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ADHESIVE, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY FIBRIN SEALANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY FIBRIN SEALANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY FIBRIN SEALANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SYNTHETIC SEALANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SYNTHETIC SEALANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SYNTHETIC SEALANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CLAMPING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CLAMPING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CLAMPING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COMPRESSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COMPRESSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COMPRESSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COMPRESSION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ANASTOMOTIC RINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ANASTOMOTIC RINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ANASTOMOTIC RINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY BUCKLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY BUCKLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY BUCKLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY BUCKLES, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY BIOABSORBABLE BUCKLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY BIOABSORBABLE BUCKLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY BIOABSORBABLE BUCKLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY METAL BUCKLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY METAL BUCKLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY METAL BUCKLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ENERGY BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ENERGY BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ENERGY BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ENERGY BASED, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ELECTROTHERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ELECTROTHERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ELECTROTHERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LASER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LASER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LASER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ULTRASONIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ULTRASONIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ULTRASONIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY STAPLING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY STAPLING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY STAPLING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CORONARY BYPASS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CORONARY BYPASS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CORONARY BYPASS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CORONARY BYPASS, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY OFF PUMP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY OFF PUMP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY OFF PUMP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ON PUMP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ON PUMP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ON PUMP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CAROTID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CAROTID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CAROTID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY FEMOROPOPLITEAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY FEMOROPOPLITEAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY FEMOROPOPLITEAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY RENAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY RENAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY RENAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY VALVE REPAIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY VALVE REPAIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY VALVE REPAIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SURGERY TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ON-PUMP CORONARY BYPASS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ON-PUMP CORONARY BYPASS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ON-PUMP CORONARY BYPASS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY OFF-PUMP CORONARY BYPASS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY OFF-PUMP CORONARY BYPASS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY OFF-PUMP CORONARY BYPASS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY MINIMALLY INVASIVE CORONARY BYPASS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY MINIMALLY INVASIVE CORONARY BYPASS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY MINIMALLY INVASIVE CORONARY BYPASS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY VALVE SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY VALVE SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY VALVE SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY VALVE SURGERY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AORTIC VALVE PROCEDURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AORTIC VALVE PROCEDURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AORTIC VALVE PROCEDURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY MITRAL VALVE PROCEDURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY MITRAL VALVE PROCEDURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY MITRAL VALVE PROCEDURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY TRICUSPID AND PULMONIC VALVE PROCEDURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY TRICUSPID AND PULMONIC VALVE PROCEDURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY TRICUSPID AND PULMONIC VALVE PROCEDURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AORTIC SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AORTIC SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AORTIC SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AORTIC SURGERY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ANEURYSM REPAIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ANEURYSM REPAIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ANEURYSM REPAIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY DISSECTION REPAIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY DISSECTION REPAIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY DISSECTION REPAIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ROOT REPLACEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ROOT REPLACEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ROOT REPLACEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CONGENITAL HEART SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CONGENITAL HEART SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CONGENITAL HEART SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CONGENITAL HEART SURGERY, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SEPTAL DEFECT REPAIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SEPTAL DEFECT REPAIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SEPTAL DEFECT REPAIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SHUNT PROCEDURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SHUNT PROCEDURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SHUNT PROCEDURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COMPLEX CONGENITAL REPAIRS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COMPLEX CONGENITAL REPAIRS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COMPLEX CONGENITAL REPAIRS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HEART TRANSPLANT AND VENTRICULAR ASSIST DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HEART TRANSPLANT AND VENTRICULAR ASSIST DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HEART TRANSPLANT AND VENTRICULAR ASSIST DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HEART TRANSPLANT AND VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HEART TRANSPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HEART TRANSPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HEART TRANSPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY VENTRICULAR ASSIST DEVICE IMPLANTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY VENTRICULAR ASSIST DEVICE IMPLANTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY VENTRICULAR ASSIST DEVICE IMPLANTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR BYPASS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR BYPASS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR BYPASS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR BYPASS, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LOWER EXTREMITY BYPASS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LOWER EXTREMITY BYPASS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LOWER EXTREMITY BYPASS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY UPPER EXTREMITY BYPASS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY UPPER EXTREMITY BYPASS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY UPPER EXTREMITY BYPASS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CAROTID BYPASS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CAROTID BYPASS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CAROTID BYPASS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HYBRID AND ENDOVASCULAR PROCEDURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HYBRID AND ENDOVASCULAR PROCEDURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HYBRID AND ENDOVASCULAR PROCEDURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HYBRID AND ENDOVASCULAR PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HYBRID CORONARY REVASCULARIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HYBRID CORONARY REVASCULARIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HYBRID CORONARY REVASCULARIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AORTIC HYBRID REPAIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AORTIC HYBRID REPAIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AORTIC HYBRID REPAIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 217. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 220. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 223. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 225. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 226. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CLIPS, 2018-2032 (USD MILLION)
  • TABLE 228. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HEMOSTATIC CLIPS, 2018-2032 (USD MILLION)
  • TABLE 229. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY STAPLERS, 2018-2032 (USD MILLION)
  • TABLE 230. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LINEAR STAPLERS, 2018-2032 (USD MILLION)
  • TABLE 231. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SUTURE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 232. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AUTOMATED SUTURING, 2018-2032 (USD MILLION)
  • TABLE 233. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 234. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ADHESIVE, 2018-2032 (USD MILLION)
  • TABLE 235. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COMPRESSION, 2018-2032 (USD MILLION)
  • TABLE 236. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY BUCKLES, 2018-2032 (USD MILLION)
  • TABLE 237. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ENERGY BASED, 2018-2032 (USD MILLION)
  • TABLE 238. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CORONARY BYPASS, 2018-2032 (USD MILLION)
  • TABLE 240. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR, 2018-2032 (USD MILLION)
  • TABLE 241. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SURGERY TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, 2018-2032 (USD MILLION)
  • TABLE 243. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY VALVE SURGERY, 2018-2032 (USD MILLION)
  • TABLE 244. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AORTIC SURGERY, 2018-2032 (USD MILLION)
  • TABLE 245. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CONGENITAL HEART SURGERY, 2018-2032 (USD MILLION)
  • TABLE 246. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HEART TRANSPLANT AND VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 247. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR BYPASS, 2018-2032 (USD MILLION)
  • TABLE 248. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HYBRID AND ENDOVASCULAR PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 249. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CLIPS, 2018-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HEMOSTATIC CLIPS, 2018-2032 (USD MILLION)
  • TABLE 254. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY STAPLERS, 2018-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LINEAR STAPLERS, 2018-2032 (USD MILLION)
  • TABLE 256. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SUTURE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AUTOMATED SUTURING, 2018-2032 (USD MILLION)
  • TABLE 258. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ADHESIVE, 2018-2032 (USD MILLION)
  • TABLE 260. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COMPRESSION, 2018-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY BUCKLES, 2018-2032 (USD MILLION)
  • TABLE 262. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ENERGY BASED, 2018-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CORONARY BYPASS, 2018-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR, 2018-2032 (USD MILLION)
  • TABLE 266. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SURGERY TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, 2018-2032 (USD MILLION)
  • TABLE 268. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY VALVE SURGERY, 2018-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AORTIC SURGERY, 2018-2032 (USD MILLION)
  • TABLE 270. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CONGENITAL HEART SURGERY, 2018-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HEART TRANSPLANT AND VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 272. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR BYPASS, 2018-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HYBRID AN